Navigation Links
First targeted and programmable nanomedicine to show clinical antitumor effects published
Date:4/4/2012

design through medicinal chemistry."

"Previous attempts to develop targeted nanoparticles have not translated into clinical success because of the inherent difficulty of designing and scaling up a particle capable of targeting, long-circulation via immune-response evasion, and controlled drug release," commented Robert Langer, Sc.D., BIND Founder and David H. Koch Institute Professor at MIT. "BIND-014 is the first therapeutic of its kind to reach clinical evaluation and has demonstrated an increases of up to ten fold in drug concentration in tumors, which lead to substantially better efficacy and safety. This represents a major advance in cancer therapy and a significant milestone for science, technology and medicine."

Key findings include:

  • Preclinical data including pharmacokinetic characteristics consistent with prolonged circulation and controlled drug release with plasma concentrations remaining up to at least 100-fold higher than conventional docetaxel for over 24 hours, as well as up to a ten-fold increase in intratumoral drug concentrations with prolonged and enhanced tumor growth suppression in multiple tumor models compared with conventional docetaxel.
  • Initial clinical data in a heavily pretreated patient population with 17 patients with advanced or metastatic solid tumor cancers indicate that BIND-014 displays pharmacological characteristics consistent with preclinical findings of differentiated pharmacokinetics and accumulation at tumor sites with clinical effects seen at doses as low as 20% of the normally prescribed docetaxel dose and in cancers in which docetaxel has minimal activity..
  • BIND-014 has been administered at doses of up to 75 mg/m2 and dose escalation is ongoing. BIND-014 is generally well tolerated with no new toxicities observed to date.

Study coauthors included scientific and clinical advisors from the Massachusetts Institute of Technology (MIT), Harvard Medical School and Dana-Farber Cancer In
'/>"/>

Contact: Kathryn Morris
kathryn@theyatesnetwork.com
914-204-6412
The Yates Network
Source:Eurekalert

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. MiMedx Exceeds Revenue Goal for First Quarter of 2012
2. FirstMark Exhibiting at the American College of Cardiology 61st Annual Scientific Sessions & Expo
3. Expanded Findings for FirstMarks Completed Clinical Study for Predicting Near-Term (2-3 Years) MI
4. Jennerex Announces First Patient Treated in Phase 1/2 Clinical Trial of JX-594 in Combination with Irinotecan in Patients with Metastatic Colorectal Cancer
5. Researchers capture first-ever images of atoms moving in a molecule
6. Be One of the First to Experience Medtrack One View at the AUTM 2012 Annual Meeting
7. First Statewide Biotech Meeting Focuses on Patient Access, Innovation
8. Inaugural Meeting of the FirstMark Scientific Board of Advisors
9. AtheroNova Achieves Milestone in Initiating First Shipment of AHRO-001
10. China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2012
11. Penn researchers build first physical metatronic circuit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... May 20, 2013 With bed bugs' presence ... that although bed bugs need to be eliminated, one must ... compromise a person's health. And so to help bed bug ... get rid of bed bugs without using harmful ... bug spray it called Bed Bug Bully. , According to ...
(Date:5/20/2013)... PA (PRWEB) May 20, 2013 Interventional ... Allegheny General Hospital (AGH) Cardiovascular Institute have ... coronary artery disease (CAD) over the past ... such as balloon angioplasty and coronary artery stent implantation. ... once again play a prominent role in the study ...
(Date:5/20/2013)... (PRWEB) May 20, 2013 In Early ... the field of biotoxin related illnesses , announced his ... country able to advance his protocol for treating Chronic ... became the third physician to achieve certification in the ... Physicians, able to practice the Shoemaker Protocol in other ...
(Date:5/17/2013)... GA (PRWEB) May 17, 2013 Dr. ... Gynecology, and Women’s Health at the Albert Einstein College ... Oncology at the Montefiore Medical Center. He is ... Cancer Center and leads the Einstein Breast Cancer Working ... on translational breast cancer research. He also serves as ...
Breaking Biology Technology:New Non Pesticide Discovery on How to Get Rid of Bed Bugs Tipped by My Cleaning Products 2Allegheny General Hospital Cardiovascular Institute Becomes Exclusive Pittsburgh Site for Study of Novel Coronary Artery Disease Device 2Allegheny General Hospital Cardiovascular Institute Becomes Exclusive Pittsburgh Site for Study of Novel Coronary Artery Disease Device 3Allegheny General Hospital Cardiovascular Institute Becomes Exclusive Pittsburgh Site for Study of Novel Coronary Artery Disease Device 4Dr. Ritchie Shoemaker Certifies Third Physician in His Treatment Protocol for Chronic Inflammatory Response Syndrome (CIRS) 2Joseph A. Sparano, MD, Named Vice Chair of ECOG-ACRIN Cancer Research Group 2Joseph A. Sparano, MD, Named Vice Chair of ECOG-ACRIN Cancer Research Group 3
... BOTHELL, WA and VANCOUVER, May 11 /PRNewswire-FirstCall/ - ... announced today that final survival data from a ... with docetaxel versus docetaxel alone as first-line chemotherapy ... be featured in an oral presentation at the ...
... manufacturer, Sepha Ltd, enters strategic European alliances and gears up for ... , ... Belfast (Vocus) May 11, 2009 -- The ... de-blistering equipment, Sepha Ltd is boosting its European distribution ...
... attempt to dismiss Bavarian Nordic,s patent infringement suit in ... Biomedica,made yet another attempt to dismiss the suit arguing ... clinical trials. The court ruled,against Oxford Biomedica and the ... patents. , Bavarian Nordic owns ...
Cached Biology Technology:OncoGenex Pharmaceuticals' Clinical Programs to be Featured in Oral Presentations at the American Society of Clinical Oncology Annual Meeting 2OncoGenex Pharmaceuticals' Clinical Programs to be Featured in Oral Presentations at the American Society of Clinical Oncology Annual Meeting 3Pharmaceutical Packaging Equipment Manufacturer Boosts European Distribution 2Pharmaceutical Packaging Equipment Manufacturer Boosts European Distribution 3The Court Supports Bavarian Nordic's Decision to Start Patent Infringement Case Against Oxford BioMedica 2
(Date:5/17/2013)... State University of New Jersey, and City University of ... Visikol TM that effectively clears organisms to be ... of chloral hydrate, which is one of the few ... regulated by the Drug Enforcement Administration (DEA) due to ... clearing agents, are vital for viewing organisms under a ...
(Date:5/17/2013)... proteins in the brain responsible for protecting nerve cells ... increase cell survival. , The discovery, made by researchers ... the EMBO journal with additional comment in ... stroke and other brain diseases. , The research builds ... protein, known as SUMO, responsible for controlling the chemical ...
(Date:5/17/2013)... project (Intelligent Cargo in Efficient and Sustainable Global Logistics ... an improvement in the efficiency of intermodal loading systems ... making. It comprises 29 European organisations with experience in ... has a budget totalling 17,000,000 and a duration of ... to specify and develop the semantic components and ontologies ...
Breaking Biology News(10 mins):New formula invented for microscope viewing, substitutes for federally controlled drug 2New formula invented for microscope viewing, substitutes for federally controlled drug 3SUMO wrestling cells reveal new protective mechanism target for stroke 2New logistics services that will cut energy consumption and CO2 emissions 2
... Leading bioscience funding bodies in the UK and USA ... transformational area of enhanced photosynthesis. The Biotechnology and ... Science Foundation (NSF) announce plans to hold an intensive ... in California later this year, to bring together leading ...
... of Cedars-Sinai Medical Center in Los Angeles, was presented ... annual Lifetime Achievement Award at its 2010 Annual Meeting. ... of contributions to genetic medicine, for his research into ... for helping to organize the field of medical genetics ...
... new tool to help marine biologists better grasp the processes ... unveil the bacterial community dynamics behind afflictions that bleach and ... March 30, 2010.) Warming waters are triggering coral ... Barrier Reef off the Australian coast. Now new mathematical models ...
Cached Biology News:BBSRC and NSF join together to promote new ideas to enhance photosynthesis 2Leader in genetics, Dr. David L. Rimoin, receives ACMG Foundation Lifetime Achievement Award 2Leader in genetics, Dr. David L. Rimoin, receives ACMG Foundation Lifetime Achievement Award 3New mathematical model helps biologists understand how coral dies in warming waters 2
... This adapter allows ... (AB-0800 and AB-1000) PCR ... in the ABI PRISM® ... contact ABgene® for information ...
... Heat activated ,• Eliminates nonspecific ... ,• Excellent specificity allows extension through ... structures ,• Leaves an 'A' overhang ... form of GeneChoice DNA Polymerase that ...
... aqueous solution. Cleaves a-(1-3)- ... carbohydrates and glycoproteins. It is particularly efficient ... the pH must be neutral or above, ... Unit Definition: One unit will ...
This adapter allows the Thermo-Fast® 96 Semi-Skirted (AB-0900 and AB-0990) PCR plates to be used directly in the ABI PRISM® 3100 sequencer without the need for software changes....
Biology Products: